Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 3,387 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Advanced Solid Neoplasm Clear all

Conditions: Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma, Triple Negative Breast Cancer, sqNSCLC, Squamous Non-small-cell Lung Cancer
Interventions: ATX-295, ATX-295 and bevacizumab (or biosimilar); Drug
Lead sponsor: Accent Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 11
States / cities: Aurora, Colorado • Sarasota, Florida • Detroit, Michigan + 8 more

Conditions: Solid Tumor, Lymphoma
Interventions: DZ-002; Drug
Lead sponsor: Da Zen Theranostics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Melanoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma of the Skin, Sarcoma of the Skin, Basal Cell Cancer of the Skin, Breast Cancer
Interventions: Poly-ICLC; Drug
Lead sponsor: Nina Bhardwaj; Other
Eligibility: 14 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Urothelial Bladder Cancer, Triple-negative Breast Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: Tremelimumab monotherapy, MEDI4736 monotherapy, MEDI4736 + tremelimumab combination therapy; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 150 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 3
States / cities: San Francisco, California • Memphis, Tennessee • Houston, Texas

Conditions: Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer
Interventions: BT5528, Nivolumab; Drug
Lead sponsor: BicycleTx Limited; Industry
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 12
States / cities: Encinitas, California • Orange, California • Denver, Colorado + 9 more

Conditions: Solid Cancers
Interventions: Atezolizumab, Bevacizumab, Interferon alfa-2b, Ipilimumab, Obinutuzumab, PEG-interferon alfa-2a; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 8
States / cities: Scottsdale, Arizona • Los Angeles, California • New Haven, Connecticut + 3 more

Conditions: Solid Tumors
Interventions: Dexamethasone, Placebo; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2028
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: Elironrasib, Daraxonrasib; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 23
States / cities: Duarte, California • Orange, California • Sacramento, California + 17 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: cisplatin, safingol; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Solid Tumors
Interventions: LCB02A; Drug
Lead sponsor: LigaChem Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 4
States / cities: Boston, Massachusetts • Lake Success, New York • Charleston, South Carolina + 1 more

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions: Crizotinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Advanced Solid Tumors
Interventions: FORX-428; Drug
Lead sponsor: FoRx Therapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Palo Alto, California • San Francisco, California • Grand Rapids, Michigan + 5 more

Conditions: Cancer, Solid Tumors
Interventions: CBP501 and Cisplatin; Drug
Lead sponsor: CanBas Co. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: Scottsdale, Arizona • Boston, Massachusetts • Las Vegas, Nevada

Conditions: Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Interventions: Cabozantinib, Pamiparib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: capecitabine, imatinib mesylate; Drug
Lead sponsor: Herbert Hurwitz; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pancreatic Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer
Interventions: AMG820 and pembrolizumab; Biological
Lead sponsor: AmMax Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 8
States / cities: Atlanta, Georgia • Boston, Massachusetts • Grand Rapids, Michigan + 4 more

Conditions: Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Interventions: TBio-4101, Pembrolizumab; Biological · Drug
Lead sponsor: Turnstone Biologics, Corp.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 11
States / cities: Irvine, California • Hollywood, Florida • Miami, Florida + 8 more

Conditions: Advanced Solid Tumor
Interventions: BT7480, Nivolumab; Drug
Lead sponsor: BicycleTx Limited; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 7
States / cities: Iowa City, Iowa • New York, New York • Cleveland, Ohio + 4 more

Conditions: Breast Cancer, Solid Tumor
Interventions: Inavolisib, Fulvestrant, Letrozole, Palbociclib, Metformin, Trastuzumab, Pertuzumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 5
States / cities: Boston, Massachusetts • New York, New York • Nashville, Tennessee

Conditions: Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer, NSCLC, Recurrent, Non-Small Cell Squamous Lung Cancer, Pancreas Cancer, Pancreatic Neoplasm, Colorectal Adenocarcinoma, CRC, Colon Cancer, Rectal Cancer, Cancer, Ovarian Cancer, Ovarian Neoplasms, Mesothelioma, Mesothelioma, Malignant, Ovary Cancer, Lung Cancer, MESOM
Interventions: A2B694, A2B543, xT CDx with HLA-LOH Assay; Biological · Diagnostic Test
Lead sponsor: A2 Biotherapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 12
States / cities: Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more

Conditions: Advanced Solid Tumor, Advanced Lymphoma
Interventions: CS5001, Rituximab, Gemcitabine, Oxaliplatin, Lenalidomide, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone; Drug · Biological
Lead sponsor: CStone Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: East Setauket, New York • New York, New York • Dallas, Texas

Conditions: Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Merkel Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Atezolizumab, Avelumab, Durvalumab, Nivolumab, Pembrolizumab, Plinabulin, Radiation Therapy; Biological · Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
Interventions: APL-101 Oral Capsules; Drug
Lead sponsor: Apollomics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 497 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 6
States / cities: Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 3 more

Conditions: Advanced Solid Tumors
Interventions: ABBV-155, Paclitaxel, Docetaxel; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 21
States / cities: Birmingham, Alabama • Springdale, Arkansas • Orange, California + 17 more

Search by objective public record fields.

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma

Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)

Study of Tremelimumab in Patients With Advanced Solid Tumors

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

Dexamethasone for Symptom Burden in Advanced Cancer Patients

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors

A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.

Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors

Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer

A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors